文献速递MDS 与骨髓增殖性肿瘤

阿扎胞苷联合或不联合度伐利尤单抗一线治疗较高危骨髓增生异常综合征的随机2期试验

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes.
PubMed 文献 · Blood Adv · 2022-01-01

该随机2期研究纳入84例较高危骨髓增生异常综合征患者,比较阿扎胞苷联合度伐利尤单抗(A组)与阿扎胞苷单药(B组)一线治疗。中位随访15.25个月,总缓解率A组61.9% vs B组47.6%(P=0.18),中位总生存A组11.6个月 vs B组16.7个月(P=0.74)。联合方案可行但毒性增加,临床结局较单药无显著改善。

要点

  • 总缓解率A组61.9%(26/42)vs B组47.6%(20/42),差异无统计学意义(P=0.18)。
  • 中位总生存A组11.6个月 vs B组16.7个月(P=0.74),无显著差异。
  • 3-4级血液学不良事件A组89.5% vs B组68.3%,联合组毒性增加。

核心结论

  • 阿扎胞苷联合度伐利尤单抗治疗较高危骨髓增生异常综合征可行,但毒性更多,临床结局较阿扎胞苷单药无显著改善。

研究设计与样本

  • 随机2期研究,纳入84例较高危骨髓增生异常综合征患者,A组42例接受阿扎胞苷75 mg/m2皮下注射(每4周第1-7天)联合度伐利尤单抗1500 mg静脉注射(每4周第1天),至少6个周期;B组42例接受阿扎胞苷75 mg/m2皮下注射单药(每4周第1-7天),至少6个周期。

主要发现

  • 中位随访15.25个月,A组8例、B组6例仍在治疗;A组中位治疗7.9个周期,B组7.0个周期,分别有73.7%和65.9%完成≥4个周期。
  • 总缓解率(主要终点)A组61.9%(26/42)vs B组47.6%(20/42),P=0.18。
  • 中位总生存A组11.6个月(95%CI 9.5个月至不可评估)vs B组16.7个月(95%CI 9.8-23.5个月),P=0.74。
  • 度伐利尤单抗相关不良事件报告率为71.1%;阿扎胞苷相关不良事件A组82%、B组81%;3-4级血液学不良事件A组89.5% vs B组68.3%。
  • TP53突变患者缓解趋势较无突变者更差;阿扎胞苷上调两组骨髓粒细胞和单核细胞(非原始细胞)的表面PD-L1(CD274)表达。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Azacitidine-mediated hypomethylation promotes tumor cell immune recognition but may increase the expression of inhibitory immune checkpoint molecules. We conducted the first randomized phase 2 study of azacitidine plus the immune checkpoint inhibitor durvalumab vs azacitidine monotherapy as first-line treatment for higher-risk myelodysplastic syndromes (HR-MDS). In all, 84 patients received 75 mg/m2 subcutaneous azacitidine (days 1-7 every 4 weeks) combined with 1500 mg intravenous durvalumab on day 1 every 4 weeks (Arm A) for at least 6 cycles or 75 mg/m² subcutaneous azacitidine alone (days 1-7 every 4 weeks) for at least 6 cycles (Arm B). After a median follow-up of 15.25 months, 8 patients in Arm A and 6 in Arm B remained on treatment. Patients in Arm A received a median of 7.9 treatment cycles and those in Arm B received a median of 7.0 treatment cycles with 73.7% and 65.9%, respectively, completing ≥4 cycles. The overall response rate (primary end point) was 61.9% in Arm A (26 of 42) and 47.6% in Arm B (20 of 42; P = .18), and median overall survival was 11.6 months (95% confidence interval, 9.5 months to not evaluable) vs 16.7 months (95% confidence interval, 9.8-23.5 months; P = .74). Durvalumab-related adverse events (AEs) were reported by 71.1% of patients; azacitidine-related AEs were reported by 82% (Arm A) and 81% (Arm B). Grade 3 or 4 hematologic AEs were reported in 89.5% (Arm A) vs 68.3% (Arm B) of patients. Patients with TP53 mutations tended to have a worse response than patients without these mutations. Azacitidine increased programmed cell death ligand 1 (PD-L1 [CD274]) surface expression on bone marrow granulocytes and monocytes, but not blasts, in both arms. In summary, combining azacitidine with durvalumab in patients with HR-MDS was feasible but with more toxicities and without significant improvement in clinical outcomes over azacitidine alone. This trial was registered at www.clinicaltrials.gov as #NCT02775903.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Zeidan AM, Boss I, Beach CL, et al. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. Blood Adv. 2022. PMID: 34972214. doi:10.1182/bloodadvances.2021005487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。